571 related articles for article (PubMed ID: 31945494)
21. Vemurafenib in non-small-cell lung cancer patients with BRAF
Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY
Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346
[TBL] [Abstract][Full Text] [Related]
22. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
23. Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer.
Lee SY; Kim YC; Lee KY; Lee SY; Lee SY; Lee MK; Lee JE; Jang SH; Jang TW; Choi CM
Thorac Cancer; 2022 Feb; 13(3):380-385. PubMed ID: 34881519
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study.
Ge Y; Li J; Gong W; Wang J; Wei X; Liu J; Wang S; Wang L; Sun H; Cheng Q; Sun Y; Dang Q; Sun Y; Gao A
Cancer Med; 2024 Jan; 13(2):e6960. PubMed ID: 38349001
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y; Tozuka T; Kushiro K; Hosokawa S; Sumi T; Uematsu M; Honjo O; Yamaguchi O; Asao T; Sugisaka J; Saito G; Shiihara J; Morita R; Katakura S; Yasuda T; Hisakane K; Miyauchi E; Morita S; Kobayashi K; Asahina H
JAMA Oncol; 2024 Apr; 10(4):439-447. PubMed ID: 38451530
[TBL] [Abstract][Full Text] [Related]
26. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
27. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
[TBL] [Abstract][Full Text] [Related]
28. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
31. Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer.
Li H; Zhang Y; Xu Y; Huang Z; Cheng G; Xie M; Zhou Z; Yu Y; Xi W; Fan Y
Cell Death Dis; 2022 Dec; 13(12):1064. PubMed ID: 36543792
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Namikawa K; Ito T; Yoshikawa S; Yoshino K; Kiniwa Y; Ohe S; Isei T; Takenouchi T; Kato H; Mizuhashi S; Fukushima S; Yamamoto Y; Inozume T; Fujisawa Y; Yamasaki O; Nakamura Y; Asai J; Maekawa T; Funakoshi T; Matsushita S; Nakano E; Oashi K; Kato J; Uhara H; Miyagawa T; Uchi H; Hatta N; Tsutsui K; Maeda T; Matsuya T; Yanagisawa H; Muto I; Okumura M; Ogata D; Yamazaki N
Cancer Med; 2023 Sep; 12(17):17967-17980. PubMed ID: 37584204
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Hess LM; Han Y; Zhu YE; Bhandari NR; Sireci A
BMC Cancer; 2021 Jan; 21(1):28. PubMed ID: 33402119
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
38. Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring
Garassino MC; Oskar S; Arunachalam A; Zu K; Kao YH; Chen C; Meng W; Pietanza MC; Zhao B; Aggarwal H
JTO Clin Res Rep; 2023 Oct; 4(10):100568. PubMed ID: 37744307
[TBL] [Abstract][Full Text] [Related]
39. The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research.
Meng Y; Yang Y; Fang Y; Lin X; Xie X; Deng H; Wu J; Zhou M; Sun N; Xie Z; Liu M; Ouyang M; Qin Y; Su C; Zhou C
Front Oncol; 2022; 12():864367. PubMed ID: 35692799
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
